Pharma R&D, what's hot in 2011 and beyond?

With closure and even divest of discovery sites in US and Europe in 2010, Big Pharma is under tremendous pressure to reduce costs and become leaner. Pharmaceutical companies are likely to continue to increase the percentage of their R&D work that is outsourced in Asia. This trend will continue to be driven by the pursuit of improving R&D cost efficiency as well as effectiveness. Beyond generating one-off savings, the emphasis will move to streamlining the outsourcing operating model, risk management, complexity management and lean process improvement. Doing more R&D with less; and smartly.

At a time of “Pharma R&D: Thinking big, acting small”, Asia Pharma R&D Leaders (APRDL) is staged back again to present another great event for pharma R&D industry leaders all over the world with special interests in pharma R&D opportunities in Asian emerging markets and with views to optimize their R&D capabilities in the region. Asia Pharma R&D Leaders 2011 (APRDL 2011) will provide you with the best practice you need to know for wining emerging market in Asia. The 2011 version of Asia Pharma R&D Event will bring in fresh perspectives and scientific advancement on popular therapeutic areas in cancers, CNS, and metabolic diseases which big pharma R&D are heavily investing in Asia. The new perspective will be discussed in parallel with pharma partnering models, licensing opportunities, risk management approaches, outsourcing strategies, IP management, and latest pharma research advancement on sequencing, biomarkers, preclinical imaging, data management etc necessary to optimize your pharma R&D cost efficiency and gain competitiveness in Asia. Come and join Asia Pharma R&D Leaders 2011-the most premier pharma R&D event in China with Asia perspectives.

     Why you can not miss Asia Pharma R&D Leaders 2011?
Develop new business models in 2011 and beyond for pharma R&D geared toward cost efficiency and ROI improvement
Navigate Asia market trends for heavily invested therapeutics areas: Oncology, CNS and Metabolic Diseases
Lay foundations for effective partnership with top China CRO, biotech and academia
Touch with latest advancement in Stem Cell, Antibody, and Peptide discoveries
Learn from best practice in managing research, balancing costs, risk and profits
Explore mass in-licensing opportunities in Asia emerging markets in response to new world R&D order
Meet 1 on 1 with your end buyers who plan to outsource R&D to Asia from Europe or US
Build right contacts in big pharma for your early stage discoveries and identify how deals can be done in Asia
Identify late stage opportunities in Asia to gain competitiveness when facing patent cliff in 2011

Speakers

Richard D. Connell PhD, Vice President Head of Research, Asia Pfizer Worldwide Research and Development	RuiPing Dong MD&PhD, SVP, Head of Emerging Market R&D Merck
Gerd Maass Global Head of Biomarker and Pathway Analysis Roche Pharma Research and Early Development	Peter Hongaard Anderson Executive Vice President,Head of Research H. Lundbeck A/S
Xiaoxiang Chen Vice President of Medicine Boehringer Ingelheim China	Ming Qiang Zhang VP / CTO Roche R&D China
Lee E. Babiss Executive Vice President of Global Laboratory Services PPD, Inc	Xin Ma Head of Global Drug Discovery - Innovation Center China Bayer Schering Pharma
Ling Su Senior Vice President and Head of Development Greater China Novartis Pharmaceuticals	Lianshan Zhang President of Global R&D Jiangsu Hengrui Medicine
Paul Bolno MD,MBA Vice President Worlwide Business Development Head of Asia GlaxoSmithKline	Jennifer Huang Clinical Research Director, Head of Global Clinical Trial Operation MSD China
Davinder Gill PhD VP/Head Global Biotherapeutics Technologies Pfizer	Richard Wang Ph. D. MBA, Director, Strategic Alliance and Collaboration for Asia, Portfolio and Operation Management AstraZeneca
Jonathon D. Sedgwick Managing Director & Chief Scientific Officer Lilly Singapore Centre for Drug Discovery (LSCDD)	Yuwen Liu CEO BioBay
Sam Lou Vice President, Buisness Development in Greater China Crown Biowcience, Inc.	Yurong Bao Director, R&D Centre Shenzhen Main Luck Pharmaceuticals Inc
Jimmy Wei Senior Vice President, Business Development and Corporate Planning Hutchison Medipharm	Daniel Caminada Senior Product Manager Cell Biology Hamilton Bonaduz AG
Peter Zhang Chairman & CEO Suzhou GenePharma Co., Ltd.	Charles Yan Senior Director, Dept Clinical Data Management Shanghai Clinical Research Center
Jiping Zha M.D. Ph.D., Vice President, Cancer Biology, Integrated Drug Discovery & Development Service Business Unit Crown Bioscience Inc.	Jeffrey C. Webster Senior Research Scientist AMRI
Chen Chen Senior Vice President, Chemistry Sundia	Marianne O. Larsen Gronning Director and Head of Diabetes Research China Novo Nordisk (China) R&D Center
Zhang Yong a senior member of BGI operating team, Vice President of Human Health Application, and Director of Multi-Omics Science BGI	Yan Cai MD, Ph.D
Maggie Gu Head of Clinical Operations (non oncology) GSK China R&D	Canwen Jiang MD&PhD VP & Head of R&D Asia Genzyme Corporation
Richard M Soll Senior Vice President, Integrated Services WuXi AppTec	Jingsong Wang M.D.Director, Discovery Medicine & Clinical Pharmacology, Bristol-Myers Squibb
Hua Cheng Senior Engineer, Project Manager SINOPEC Shanghai Engineering Co., Ltd.	Jingkang Shen Deputy Director Shanghai Institute of Materia Medica
Yizhun Zhu Dean of School of Pharmacy and Director, Institute of Drug R&D Fudan University	Frank Grams Executive Director Roche Partnering, Asia
Ningling Wang Partner Finnegan	Judy Kai LN, MA, Vice President, Contract Research Organization PPCj
James W.Baumgartner Ph.D. Senior Director, In Vitro Pharmacology Ricerca Biosciences,LLC	Susan Wang Ph.D. Strategic Director Ricerca Biosciences,LLC
Swami Subramaniam Director - Licengsing and External Research ( India and SE Asia ) Merck & Co., Inc	Jennifer Hu Director of Licensing & External Research ( Mainland China, Hong Kong & Taiwan ) Merck & Co., Inc

Who should attend?
Meet and network with the leaders in the pharma R&D industry:

• By Attendees:
• Chief ExecutiveOfficer
• Chief MedicalOfficer
• Chief ScientificOfficer
• SVP, VP, Head, Director of
• Research and Development
• R&D Business Development
• Medical Affairs
• Outsourcing andExternalization
• Oncology/CNS/Diabetes Research
• Biomarker and Translational Research
• Licensing and Partnership
• Clinical Trials

• By Industry:
• Bioparks
• Pharma/Biopharmas
• Biotechs
• Clinical Data Management
• Contract Research Organization
• Database / Data Mining
• Drug Discovery Support Software
• Electronic Data Capturing Systems
• High Performance Computing
• Imaging Systems/Image Analysis
• Legal Companies
• Mass Spectrometry Analysis
• Microarray Instruments
• Protein/DNA Analyzing Software
• Research Equipment
• Stem Cell Research Technologies
• Venture Capital Firms

Media Partners